8-K: Conduit Pharmaceuticals Faces Nasdaq Delisting Threat Amidst Low Share Price, Plans Reverse Stock Split

Conduit Pharmaceuticals is facing potential delisting from Nasdaq due to its low share price, and is planning a reverse stock split to regain compliance.

Summary

• Conduit Pharmaceuticals received a delisting notice from Nasdaq on December 17, 2024, because its stock price closed at $0.10 or less for ten consecutive trading days.
• The company was previously notified on August 12, 2024, for not complying with the minimum $1.00 bid price rule.
• Conduit has until February 10, 2025, to regain compliance.
• The company intends to request a hearing with the Nasdaq Hearings Panel to present a plan to regain compliance and request an extension.
• At the annual meeting on December 18, 2024, shareholders approved a reverse stock split with a ratio between 1-for-10 and 1-for-100, to be determined by the Board of Directors.
• The company's common stock and warrants will continue to trade on Nasdaq under the symbols CDT and CDTTW, respectively, pending the outcome of the hearing process.
• The company regained compliance with audit committee listing requirements on December 20, 2024, following the appointment of Simon Fry as a director.
• Shareholders elected six directors and ratified the selection of Marcum LLP as the company's independent auditor for the year ending December 31, 2024.

Sentiment

Score: 3

Explanation: The document indicates significant negative news with the delisting notice, although the company is taking steps to address the issue. The sentiment is negative due to the potential delisting and low stock price.

Positives

• The company intends to request a hearing to appeal the delisting notice.
• Shareholders approved a reverse stock split which could help regain compliance with Nasdaq listing rules.
• The company has regained compliance with audit committee listing requirements.
• The company has a plan to present to the Nasdaq Hearings Panel to regain compliance.

Negatives

• The company received a delisting notice from Nasdaq due to its low stock price.
• The company's stock price closed at $0.10 or less for ten consecutive trading days.
• There is no guarantee that the company will be successful in its appeal or that the reverse stock split will be sufficient to regain compliance.
• The company was previously notified for not complying with the minimum $1.00 bid price rule.

Risks

• There is a risk that the company will be delisted from Nasdaq if it does not regain compliance with listing rules.
• The reverse stock split may not be sufficient to increase the stock price to the required level.
• The company's stock price may continue to decline.
• There is no guarantee that the Nasdaq Hearings Panel will grant an extension.

Future Outlook

The company plans to request a hearing with the Nasdaq Hearings Panel to present a plan to regain compliance and request an extension. The company may implement a reverse stock split to attempt to regain compliance with the Low Priced Stocks Rule.

Management Comments

• The company intends to timely request a hearing before the Panel.
• The company will present its plan to evidence compliance with the Rules and request an extension of time within which to do so.

Industry Context

This announcement highlights the challenges faced by companies with low stock prices in maintaining their listing on major exchanges. It is not uncommon for companies to implement reverse stock splits to regain compliance with listing requirements.

Comparison to Industry Standards

• Many companies facing delisting from Nasdaq due to low share prices have implemented reverse stock splits, such as Cassava Sciences (SAVA) which implemented a 1-for-5 reverse stock split in 2020 to regain compliance.
• Other companies have been delisted from Nasdaq for failing to meet minimum bid price requirements, such as China Xiangtai Food Co., Ltd. (PLIN) which was delisted in 2023.
• The range of the reverse stock split (1-for-10 to 1-for-100) is within the typical range for companies attempting to regain compliance.

Management Changes

Stakeholder Impact

• Shareholders are negatively impacted by the potential delisting and low stock price.
• Employees may be concerned about the company's future.
• Creditors may be concerned about the company's financial stability.

Next Steps

• The company will request a hearing with the Nasdaq Hearings Panel.
• The company will present a plan to regain compliance with listing rules.
• The company may implement a reverse stock split.
• The Nasdaq Hearings Panel will make a decision following the hearing.

Key Dates

Keywords

delisting, Nasdaq, reverse stock split, compliance, hearing, stock price, listing rules, audit committee, stock option